4.1. Study Design
liver metastatic lesion
This open-label, single-arm, phase II multicenter exploratory study (Q-CROC-06) enrolled patients with mCRC who had failed first-line therapy with an oxaliplatin and/or irinotecan-containing regimen with or without bevacizumab. A pre-treatment biopsy (pre-biopsy) of a liver metastatic lesion was performed on eligible mCRC patients unless they were previously enrolled in the multicenter phase IV clinical study Q-CROC-01 (NCT00984048) [